PIERANTONI, FRANCESCO
PIERANTONI, FRANCESCO
Università di Padova
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial
2023 Vignani, F.; Tambaro, R.; De Giorgi, U.; Giannatempo, P.; Bimbatti, D.; Carella, C.; Stellato, M.; Atzori, F.; Aieta, M.; Masini, C.; Hamzaj, A.; Ermacora, P.; Veccia, A.; Scandurra, G.; Gamba, T.; Ignazzi, G.; Pignata, S.; Di Napoli, M.; Lolli, C.; Procopio, G.; Pierantoni, F.; Zonno, A.; Santini, D.; Di Maio, M.
Advanced Non-Clear Cell Renal Cell Carcinoma Treatments and Survival: A Real-World Single-Centre Experience
2023 Bimbatti, D.; Pierantoni, F.; Lai, E.; Ballestrin, M.; Cavasin, N.; Erbetta, E.; De Toni, C.; Basso, U.; Maruzzo, M.
Clinical relevance of molecular biomarkers in urothelial carcinomas treated with chemotherapy, immunotherapy or targeted-therapies
2024 Pierantoni, Francesco
Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience
2021 Pierantoni, F.; Basso, U.; Maruzzo, M.; Lamberti, E.; Bimbatti, D.; Tierno, G.; Bergo, E.; Brunello, A.; Zagonel, V.
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
2023 Porta, C.; Bamias, A.; Zakopoulou, R.; Myint, Z. W.; Cavasin, N.; Iacovelli, R.; Pichler, M.; Kopecky, J.; Kucharz, J.; Rizzo, M.; Galli, L.; Buttner, T.; de Giorgi, U.; Kanesvaran, R.; Fiala, O.; Grande, E.; Zucali, P. A.; Kopp, R. M.; Fornarini, G.; Bourlon, M. T.; Scagliarini, S.; Molina-Cerrillo, J.; Aurilio, G.; Matrana, M. R.; Pichler, R.; Cattrini, C.; Buchler, T.; Massari, F.; Mollica, V.; Seront, E.; Calabro, F.; Pinto, A.; Berardi, R.; Zgura, A.; Mammone, G.; Ansari, J.; Atzori, F.; Chiari, R.; Caffo, O.; Procopio, G.; Sunela, K.; Bassanelli, M.; Ortega, C.; Grillone, F.; Landmesser, J.; Merler, S.; Messina, C.; Kuronya, Z.; Mosca, A.; Bhuva, D.; Santini, D.; Vau, N.; Morelli, F.; Incorvaia, L.; Rebuzzi, S. E.; Roviello, G.; Soares, A.; Zabalza, I. O.; Rizzo, A.; Bisonni, R.; Pierantoni, F.; Sorgentoni, G.; Monteiro, F. S.; Battelli, N.; Buti, S.; Santoni, M.
Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature
2022 Bimbatti, D.; Maruzzo, M.; Pierantoni, F.; Diminutto, A.; Dionese, M.; Deppieri, F. M.; Lai, E.; Zagonel, V.; Basso, U.
Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience
2022 Bimbatti, D.; Dionese, M.; Lai, E.; Cavasin, N.; Basso, U.; Mattana, A.; Pierantoni, F.; Zagonel, V.; Maruzzo, M.
Patient Reported Outcomes, Paternity, Relationship, and Fertility in Testicular Cancer Survivors: Results from a Prospective Observational Single Institution Trial
2022 Bimbatti, D.; Lai, E.; Pierantoni, F.; Maruzzo, M.; Msaki, A.; De Toni, C.; Dionese, M.; Feltrin, A.; Basso, U.; Zagonel, V.
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
2023 Stellato, M.; Buti, S.; Maruzzo, M.; Bersanelli, M.; Pierantoni, F.; De Giorgi, U.; Di Napoli, M.; Iacovelli, R.; Vitale, M. G.; Ermacora, P.; Malgeri, A.; Maiorano, B. A.; Prati, V.; Mennitto, A.; Cavo, A.; Santoni, M.; Carella, C.; Fratino, L.; Procopio, G.; Verzoni, E.; Santini, D.
Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy
2023 Dionese, M.; Basso, U.; Pierantoni, F.; Lai, E.; Cavasin, N.; Erbetta, E.; Jubran, S.; Bonomi, G.; Bimbatti, D.; Maruzzo, M.
Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters
2021 Sharova, E.; Maruzzo, M.; Del Bianco, P.; Cavallari, I.; Pierantoni, F.; Basso, U.; Ciminale, V.; Zagonel, V.
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
2022 Maruzzo, M.; Pierantoni, F.; Bortolami, A.; Palleschi, D.; Zivi, A.; Nicodemo, M.; Sartori, D.; De Vivo, R.; Zustovich, F.; Bimbatti, D.; Pastorelli, D.; Vultaggio, G. D.; Soraru', M.; Ballestrin, M.; Modonesi, C.; Randisi, P.; Barile, C.; Perri, G.; Basso, U.; Zagonel, V.
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study
2022 Raggi, D.; Giannatempo, P.; Marandino, L.; Pierantoni, F.; Maruzzo, M.; Lipari, H.; Banna, G. L.; De Giorgi, U.; Casadei, C.; Naglieri, E.; Buti, S.; Bersanelli, M.; Stellato, M.; Santini, D.; Vignani, F.; Roviello, G.; Veccia, A.; Caffo, O.; Losanno, T.; Calabro, F.; Mucciarini, C.; Pignata, S.; Necchi, A.; Maio, M. D.
The prognostic Value of Thyroid Hormone Levels in Immunotherapy-Treated Patients With Metastatic Urothelial Carcinoma
2023 Pierantoni, F.; Dionese, M.; Basso, U.; Lai, E.; Cavasin, N.; Erbetta, E.; Mattana, A.; Bimbatti, D.; Zagonel, V.; Lonardi, S.; Maruzzo, M.